目前对三阴性乳腺癌（TNBC）的治疗策略基于常规化疗、免疫治疗或两者的结合。化疗的治疗方案通常是两种或更多药物的联合应用，剂量密集或低剂量以达到协同作用。早期TNBC常采用蒽环类化合物、烷化剂、抗微管蛋白类药物和抗代谢物药物；而晚期TNBC通常使用抗代谢物药物、非紫杉醇微管蛋白抑制剂和交联剂铂类药物。对于无法接受手术且癌症已转移的晚期TNBC患者，最近出现了一些新的选择，如聚(ADP核糖)聚合酶（PARP）抑制剂和免疫检查点抑制剂。本综述论文概述了TNBC缺氧启发治疗策略的当前趋势，重点介绍了临床试验的情况。引言：本综述文章概述了当前临床上关于TNBC缺氧启发治疗策略的最新现状，重点介绍了癌症免疫治疗领域的临床可行性和临床试验的状态。版权所有 © 2023 Elsevier Ltd. 保留所有权利。

Current treatment strategies for triple-negative breast cancer (TNBC) are based upon conventional chemotherapy, immunotherapy, or a combination of both. The treatment regimen for chemotherapy is often a combination of two or more drugs, either dose dense or low dose for synergy. Anthracyclines, alkylating agents, antimicrotubule agents, and antimetabolites for early-stage TNBC; and antimetabolites, non-taxane microtubule inhibitors, and cross-linker platinums for late-stage TNBC are usually administered in the clinical setting. Newer options for patients with advanced TNBC, such as poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors, have recently emerged for cases where surgery is not a viable option and the disease has metastasized. This review outlines the current trends in hypoxia-inspired treatment strategies for TNBC with a focus on clinical trials. Teaser: This review outlines the current clinical state-of-the-art hypoxia-inspired treatment strategies for TNBC, with an emphasis on clinical viability and status of clinical trials in the field of cancer immunotherapy.Copyright © 2023 Elsevier Ltd. All rights reserved.